Wound healing is a multistep biological process involving inflammation, tissue formation, and remodeling. While inflammation is essential for clearing debris and recruiting repair cells, excessive or ...

DelveInsight’s 'NLRP3 Protein Inhibitors Pipeline Insight 2024' report provides comprehensive global coverage of pipeline NLRP3 protein inhibitors in various stages of clinical development, major ...

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 ...

Northwestern Medicine investigators recently discovered that the mitochondrial respiratory chain — a series of protein complexes essential for a cellular respiration and energy production — is ...

BioAge Labs (NASDAQ:BIOA) outlined its strategy and near-term clinical plans at Oppenheimer’s 36th Annual Life Science Conference, emphasizing its focus on using human aging biology to develop ...

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and ...

BUFFALO, NY-August 8, 2023 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 14, entitled, “Inhibiting ...

The NLRP3 inflammasome is a multiprotein complex that plays a pivotal role in regulating the innate immune system and inflammatory signaling. Upon activation by pathogen-associated molecular patterns ...

Ventus Therapeutics has raised a $100 million series B to take small molecules against traditionally undruggable targets into clinical trials. The pipeline features NLRP3 inhibitors that Ventus is ...

Inflazome, a start-up developing small-molecule drugs that combat inflammation, raised $46 million in its series B financing to launch its first clinical trials in 2019. Inflazome is focused on ...